Bausch + Lomb Acquires ELIOS System, Expanding Glaucoma Treatment Options

博士伦收购ELIOS系统，扩大青光眼治疗选择

December 12, 2024

2024年12月12日

Bausch + Lomb Corp. has announced the acquisition of Elios Vision Inc., the developer of the ELIOS procedure—a minimally invasive glaucoma surgery (MIGS) procedure utilizing an excimer laser. This acquisition underscores Bausch + Lomb’s commitment to providing advanced solutions for glaucoma treatment, enhancing care for patients worldwide..

博士伦公司（Bausch+Lomb Corp.）宣布收购Elios Vision Inc.，这是一种利用准分子激光的微创青光眼手术（MIGS）的开发公司。此次收购突显了博士伦致力于为青光眼治疗提供先进解决方案，加强对全球患者的护理。。

Advancing Glaucoma Treatment

推进青光眼治疗

The ELIOS system is the first clinically validated, minimally invasive glaucoma surgery using a non-thermal, laser-based approach. It offers a tissue-friendly and highly adaptable option for treating glaucoma, eliminating the need for implants. The MIGS category, including the ELIOS system, is widely recognized for its safety, effectiveness, and shorter recovery times compared to other surgical techniques..

ELIOS系统是第一个使用非热激光方法进行临床验证的微创青光眼手术。它为治疗青光眼提供了一种组织友好且适应性强的选择，无需植入物。与其他手术技术相比，包括ELIOS系统在内的MIGS类别因其安全性，有效性和更短的恢复时间而得到广泛认可。。

Synergy with Cataract Surgery

与白内障手术的协同作用

MIGS procedures, including ELIOS, are often performed alongside cataract surgery—the most common surgical procedure globally. With an estimated 19% of cataract surgery patients also suffering from glaucoma or ocular hypertension, this presents a significant opportunity for integrated treatment solutions..

包括ELIOS在内的MIGS手术通常与白内障手术一起进行，白内障手术是全球最常见的外科手术。据估计，19%的白内障手术患者也患有青光眼或高眼压，这为综合治疗方案提供了重要机会。。

Leadership Insights

领导力洞察力

Commitment to Innovation

Luc Bonnefoy, President of the Surgical Division at Bausch + Lomb, emphasized the strategic value of the acquisition:

博士伦外科总裁Luc Bonnefoy强调了此次收购的战略价值：

“The ELIOS system offers a differentiated approach for the treatment of glaucoma, a condition expected to increase in prevalence by 47% from 2020 to 2040. This acquisition demonstrates our commitment to investing in technologies that help eye care professionals better address the evolving needs of their patients.”.

“ELIOS系统为青光眼的治疗提供了一种有区别的方法，预计从2020年到2040年，青光眼的患病率将增加47%。此次收购表明，我们致力于投资于帮助眼科专业人员更好地满足患者不断变化的需求的技术。”。

Expert Endorsement

专家认可

Dr. Ike K. Ahmed, an ophthalmologist at the University of Toronto and the Moran Eye Center, highlighted the system’s innovative potential:

多伦多大学和莫兰眼科中心的眼科医生Ike K.Ahmed博士强调了该系统的创新潜力：

“ELIOS provides a tissue-friendly, precision non-thermal laser-based and highly adoptable procedure for the treatment of glaucoma. The synergy between cataract surgery and MIGS can help ophthalmologists provide streamlined care and improve patient quality of life.”

“ELIOS为青光眼的治疗提供了一种组织友好、精确、基于非热激光的高度可采用的程序。白内障手术和MIGS之间的协同作用可以帮助眼科医生提供简化的护理并改善患者的生活质量。”

Global Reach and Vision

全球范围和愿景

Elliot Friedman, former Chairman and CEO of Elios Vision, expressed optimism about the partnership:

Eliot Friedman，Elios Vision前董事长兼首席执行官，对合作关系表示乐观：

“Bausch + Lomb’s extensive reach in cataract surgery will introduce ELIOS to a broader range of eye care professionals and help change the treatment paradigm for the estimated 80 million people worldwide living with glaucoma. The goal is to make combining cataract and glaucoma treatment the new standard of care, which is even more attainable given Bausch + Lomb’s presence in nearly 100 countries.”.

“博士伦在白内障手术方面的广泛影响力将为更多的眼科护理专业人员引入ELIOS，并有助于改变全球约8000万青光眼患者的治疗模式。目标是使白内障和青光眼联合治疗成为新的护理标准，鉴于博士伦在近100个国家的存在，这一标准更容易实现。”。

Current Status and Future Prospects

现状和未来前景

• CE Marked: The ELIOS system is currently CE marked and available in the European Union.

•CE标记：ELIOS系统目前已通过CE标记，可在欧盟使用。

• FDA Approval: Elios Vision is actively seeking FDA approval to expand the technology’s availability in the United States.

•FDA批准：Elios Vision正在积极寻求FDA批准，以扩大该技术在美国的可用性。

Advisory and Legal Support

咨询和法律支持

Leerink Partners served as the exclusive financial advisor to Elios Vision, while Wilson Sonsini Goodrich & Rosati acted as legal advisor for the transaction.

Leerink Partners担任Elios Vision的独家财务顾问，Wilson Sonsini Goodrich＆Rosati担任该交易的法律顾问。

This acquisition positions Bausch + Lomb as a leader in advancing glaucoma care, offering innovative and integrated solutions for eye care professionals and patients alike.

此次收购使博士伦成为推进青光眼护理的领导者，为眼科护理专业人员和患者提供创新和集成的解决方案。